Adult: For the treatment of reversible cases that may occur in association with bronchitis and emphysema. Dosage is individualised according to patient response. 20 mg 3-4 times daily. Child: 6-9 years or weighing <27 kg: 10 mg 3-4 times daily; >9 years or weighing ≥27 kg: Same as adult dose.
Oral Bronchial asthma
Adult: Dosage is individualised according to patient response. 20 mg 3-4 times daily. Child: 6-9 years or weighing <27 kg: 10 mg 3-4 times daily; >9 years or weighing ≥27 kg: Same as adult dose.
Administration
May be taken with or without food.
Contraindications
Pre-existing cardiac arrhythmias associated with tachycardia.
Special Precautions
Patient with CV disease (e.g. ischaemic heart disease, hypertension, cardiac arrhythmias), hyperthyroidism, diabetes mellitus, glaucoma, hypokalaemia, or seizures. Not recommended for routine or long-term daily use for the management of acute asthma. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Immediate hypersensitivity reactions (e.g. urticaria, rash, bronchospasm, angioedema), changes in systolic and diastolic blood pressure. Cardiac disorders: Tachycardia, palpitations. Gastrointestinal disorders: Nausea, diarrhoea. Musculoskeletal and connective tissue disorders: Tremor. Nervous system disorders: Headache, nervousness, dizziness, insomnia, fatigue. Respiratory, thoracic and mediastinal disorders: Exacerbation of asthma.
Enhanced adverse effect with other sympathomimetic agents, MAOIs, and TCAs. Diminished bronchodilatory effect with non-selective β-blockers (e.g. propranolol).
Action
Description: Orciprenaline is a bronchodilator which exerts its effect by stimulating the β-adrenergic receptors causing an increased conversion of ATP to 3'-5'-cyclic adenosine monophosphate(cAMP), resulting to bronchial smooth muscle relaxation.
Synonym: metaproterenol. Onset: Approx 30 minutes (bronchodilation). Duration: Approx 2-6 hours. Pharmacokinetics: Absorption: Well absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 1 hour. Bioavailability: Approx 40%. Metabolism: Undergoes extensive first-pass metabolism in the liver. Excretion: Via urine (as glucuronic acid conjugates).
R03CB03 - orciprenaline ; Belongs to the class of adrenergics for systemic use, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases. R03AB03 - orciprenaline ; Belongs to the class of adrenergic inhalants, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
References
Anon. Metaproterenol (Briggs Drugs in Pregnancy and Lactation). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 14/06/2021.Anon. Orciprenaline (Metaproterenol). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 14/06/2021.Buckingham R (ed). Orciprenaline sulfate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com . Accessed 14/06/2021.Metaproterenol Sulfate Syrup (Brant Ranch Prepack). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 17/06/2021.Metaproterenol Sulfate Syrup (Lannett Company, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 14/06/2021.Metaproterenol. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 17/06/2021.